Discover TEOXANE’s holistic approach to treat infraorbital hollows combining:
•TEOSYAL ® PURESENSE REDENSITY 2, the first and only hyaluronic acid gel designed for under eyes hollows, 9 years of expertise1-4
•TEOSYAL RHA® 4, a dynamic filler for soft volume enhancement 5,6
•Complemented with R[II] Eyes an eye tinted cream
References
1.Teoxane internal data source. Teosyal Redensity 2 deliveries from 2012 to 2020: 1'011'774 boxes
2.Berguiga et al. Orbit, 2017; 36(1):22-26.
3.TEOSYAL ® PURESENSE REDENSITY 2 – instruction for use
4.TEOXANE R&D report RDRE 2023. Data on File. Physical analysis of HA fillers intended for infraborbital uses. Torsion and compression tests assessed on a rheometer. The measurement of the rheological parameter Delta index represents the balance between gel viscosity and elasticity. . “
5.TEOSYAL RHA® 4 – instruction for use
6.RDRE 2015 - Rheological analysis of Volumizers _ Ultra Deep_RHA4_Lyft_Voluma
7. Michaud et al. J Cosmet Dermatol. 2015; 14(1): 9–21
8. Arcane Research Study conducted in France in March 2018 on 8.646 women from 18 to 75 y/o
9. Teoxane data source TEO-RHA-1902 Injection Guidelines
10. Funt. J Clin Aesthet Dermatol. 2011; 4(12):32-63
11. Bravo et al. J Clin Aesthet Dermatol. 2015; 8(6):30-5
12. Glaser et al. Dermatol Surg 2018; 44:1547-1554
13. Beleznay et al. Dermatol Surg. 2015; 41:1097-1117
14. Teoxane Post Market Surveillance data November 2020. 1445 practitioners worldwide
15. Ramanadham et al. Plast Reconstr Surg. 2015; 136:49S-55S
16.Teoxane Worldwide Survey "Periorbital Treatments in Clinics" by 180 injectors, June 2020
17. Cotofana et al. Facial Plast Surg. 2016; 32:253-260
18. Lemaire. E2e Medical Publishing, Master Collection 2, Paris, 2011
19. Kaufman-Janette et al. J Cosmet Dermatol. 2019; doi: 10.1111/jocd.1310
20. Rzany et al. Dermatol Surg; 2019; 45(10):1304-1314
21. TEOXANE Post-Marketing Surveillance from 2016 to 2020-Q3
22. Data on file 2020. Syneos study report 7010664.SA.259
23. Sharad. J Cutan Aesthet Surg. 2012; 5:229238
24. Sadick et al. Cosmet Dermatol. 2007;6(4):218-22
25. The properties of ingredients derive from data communicated by the raw material manufacturers
26.Efficacy study. Results measured after 28 days of use
* REDENSITY 2 = TEOSYAL® PureSense REDENSITY 2
# Depending on the country registration, TEOSYAL RHA® 4 exists in 1 mL
